321 related articles for article (PubMed ID: 16931258)
1. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve.
Donnenfeld ED; Perry HD; Wittpenn JR; Solomon R; Nattis A; Chou T
J Cataract Refract Surg; 2006 Sep; 32(9):1474-82. PubMed ID: 16931258
[TBL] [Abstract][Full Text] [Related]
2. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients.
Wittpenn JR; Silverstein S; Heier J; Kenyon KR; Hunkeler JD; Earl M;
Am J Ophthalmol; 2008 Oct; 146(4):554-560. PubMed ID: 18599019
[TBL] [Abstract][Full Text] [Related]
3. A randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells.
el-Harazi SM; Ruiz RS; Feldman RM; Villanueva G; Chuang AZ
Ophthalmic Surg Lasers; 1998 Jul; 29(7):539-44. PubMed ID: 9674003
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery.
Maca SM; Amon M; Findl O; Kahraman G; Barisani-Asenbauer T
Am J Ophthalmol; 2010 May; 149(5):777-84. PubMed ID: 20152959
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery.
Flach AJ; Dolan BJ; Donahue ME; Faktorovich EG; Gonzalez GA
Ophthalmology; 1998 Sep; 105(9):1775-9. PubMed ID: 9754191
[TBL] [Abstract][Full Text] [Related]
6. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.
Duong HV; Westfield KC; Chalkley TH
J Cataract Refract Surg; 2007 Nov; 33(11):1925-9. PubMed ID: 17964399
[TBL] [Abstract][Full Text] [Related]
7. Incidence of postoperative posterior capsular opacification following treatment with diclofenac 0.1% and ketorolac 0.5% ophthalmic solutions: 3-year randomized, double-masked, prospective clinical investigation.
Flach AJ; Dolan BJ
Trans Am Ophthalmol Soc; 2000; 98():101-5; discussion 105-7. PubMed ID: 11190013
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients.
Solomon KD; Donnenfeld ED; Raizman M; Sandoval HP; Stern K; VanDenburgh A; Cheetham JK; Schiffman R;
J Cataract Refract Surg; 2004 Aug; 30(8):1653-60. PubMed ID: 15313287
[TBL] [Abstract][Full Text] [Related]
9. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery.
Almeida DR; Johnson D; Hollands H; Smallman D; Baxter S; Eng KT; Kratky V; ten Hove MW; Sharma S; El-Defrawy S
J Cataract Refract Surg; 2008 Jan; 34(1):64-9. PubMed ID: 18165083
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery.
Stewart R; Grosserode R; Cheetham JK; Rosenthal A
Clin Ther; 1999 Apr; 21(4):723-32. PubMed ID: 10363737
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation.
Sandoval HP; De Castro LE; Vroman DT; Solomon KD
J Ocul Pharmacol Ther; 2006 Aug; 22(4):251-7. PubMed ID: 16910866
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery.
Weber M; Kodjikian L; Kruse FE; Zagorski Z; Allaire CM
Acta Ophthalmol; 2013 Feb; 91(1):e15-21. PubMed ID: 22970738
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study.
Tzelikis PF; Vieira M; Hida WT; Motta AF; Nakano CT; Nakano EM; Alves MR
Br J Ophthalmol; 2015 May; 99(5):654-8. PubMed ID: 25385061
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial.
Ticly FG; Lira RP; Zanetti FR; Machado MC; Rodrigues GB; Arieta CE
J Ocul Pharmacol Ther; 2014 Aug; 30(6):495-501. PubMed ID: 24735005
[TBL] [Abstract][Full Text] [Related]
15. Prospective, Randomized Study Comparing the Effect of 0.1% Nepafenac and 0.4% Ketorolac Tromethamine on Macular Thickness in Cataract Surgery Patients With Low Risk for Cystoid Macular Edema.
Ramakrishnan S; Baskaran P; Talwar B; Venkatesh R
Asia Pac J Ophthalmol (Phila); 2015; 4(4):216-20. PubMed ID: 26225780
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute pseudophakic cystoid macular edema: Diclofenac versus ketorolac.
Rho DS
J Cataract Refract Surg; 2003 Dec; 29(12):2378-84. PubMed ID: 14709300
[TBL] [Abstract][Full Text] [Related]
17. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial.
Heier J; Cheetham JK; Degryse R; Dirks MS; Caldwell DR; Silverstone DE; Rosenthal A
Am J Ophthalmol; 1999 Mar; 127(3):253-9. PubMed ID: 10088733
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
Holzer MP; Solomon KD; Sandoval HP; Vroman DT
J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification.
Almeida DR; Khan Z; Xing L; Bakar SN; Rahim K; Urton T; El-Defrawy SR
J Cataract Refract Surg; 2012 Sep; 38(9):1537-43. PubMed ID: 22795976
[TBL] [Abstract][Full Text] [Related]
20. Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema.
Yavas GF; Oztürk F; Küsbeci T
J Cataract Refract Surg; 2007 May; 33(5):804-7. PubMed ID: 17466852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
